OBJECTIVE: Non-coding RNA (ncRNA) are small regulatory molecules, including microRNA (miRNA) and long non-coding RNA (lncRNA), that may serve as biomarkers for adverse pregnancy outcomes. Characterizing ncRNA local expression in response to pregnancy will advance understanding of reproductive physiology. This study aimed to identify pregnancy-associated changes in cervical miRNA and lncRNA, as well as their impact on biologic processes. STUDY DESIGN: This is a matched, nested case-control study of 21 pregnant and 21 non-pregnant women from an ongoing prospective pregnancy cohort. Pregnant women were >18 years of age, had cervical swabs collected at a mean of 15 weeks' gestation, and had term singleton deliveries. Non-pregnant women were 18-45 years of age receiving routine gynecologic care. Participants were matched on age, race, and parity. miRNA were measured with a TaqMan OpenArray PCR platform. Putative mRNA targets were identified via TargetScan and queried using Panther Gene Ontology Classification to identify gene enrichment in biological processes. mRNA and lncRNA were measured with ArrayStar LncRNA Microarray. We adjusted analyses for leukocyte burden and used multivariable linear regression with Bonferroni correction and a 2-fold change cut off to compare miRNA, mRNA, and lncRNA expression. RESULTS: Five miRNA (miR-126, miR-150, miR-21, miR-101, and miR-335) were differentially expressed in cervical samples from pregnant women; all were downregulated. Putative targets of these miRNA are enriched in genes mediating organogenesis, cell adhesion and motility, glucocorticoid signaling, and ncRNA machinery. Five mRNA were differentially expressed; all were upregulated in pregnancy. Two of these transcripts, SRRM4 and GRHL2, are predicted targets of the identified miRNA. Three lncRNA (RP11-403P17.3, RP11-290L1.3, and MYLK-AS1) were upregulated in pregnancy. CONCLUSION: Pregnancy was associated with a novel cervical ncRNA signature. Gene ontology clustering revealed biological pathways through which these molecules may orchestrate normal pregnancy physiology, providing opportunity for early disease recognition. These data suggest that the cervix may function as a window into the health of the developing pregnancy. OBJECTIVE: Ventricular septal defect (VSD) represents the most common type of congenital cardiac disease, affecting more than 1 in 300 live births. The objective of this study was to examine the incidence and nature of abnormal Chromosomal Microarray Analysis (CMA) results in a large cohort of pregnancies with VSD. STUDY DESIGN: Data acquisition was performed through Ministry of Health computerized database. All CMA results performed due to VSD during the years 2013-2017 were included. The rate of clinically significant CMA results in subgroups with isolated and non-isolated VSD was compared to two control populations e a systematic review of 9272 pregnancies and a local cohort of 5541 fetuses with normal ultrasound. RESULTS: Overall, 691 CMA analyses performed due to a sonographic indication of VSD were found. Of 568 pregnancies with isolated VSD, 8 (1.4%) clinically significant copy number variants (CNV) were detected (mostly submicroscopic), a non-significant difference compared to low risk pregnancies. Of the 123 pregnancies with non-isolated VSDs, 18 (14.6%) clinically significant CMA results were detected, a considerably increased risk compared to lowrisk pregnancies, with a high proportion of karyotype-detectable anomalies (12 of 18 cases, 66.7%). CONCLUSION: The outcomes of our study, representing the largest number of CMA results in pregnancies with VSD, suggest that the rate of abnormal CMA findings in isolated VSD does not differ from low risk pregnancies. This observation is true for population undergoing routine Down syndrome screening tests and early sonographic evaluation, as well as widely available non-invasive prenatal screening. On the contrary, CMA analysis yields a high detection rate in pregnancies with non-isolated VSD. This issue should further explored by prospective large-scale studies, including the effect of VSD types on fetal genetic testing results. OBJECTIVE: Polyhydramnios involves about 1-2% of overall pregnancies. The objective of our study was to analyze the risk for clinically significant chromosomal microarray analysis (CMA) findings in this common sonographic abnormality. STUDY DESIGN: Data from all CMA analyses performed due to polyhydramnios between January 2013 and September 2017 were retrospectively obtained from the Ministry of Health database. Risk estimation was performed comparing the rate of abnormal microarray findings to two control populations, based on a systematic review of 9272 pregnancies and a large local cohort of 5541 fetuses with normal ultrasound. Subgroup analyses were performed by the degree of polyhydramnios, week of diagnosis, and presence of associated sonographic anomalies. RESULTS: Of 498 pregnancies with isolated polyhydramnios, 17 (3.4%) clinically significant CMA aberrations were noted. Pregnancies with mild polyhydramnios (amniotic fluid index (AFI) 25-29.9 or maximal vertical pocket 8-11.9 cm, 124 cases) did not yield an increased risk for abnormal CMA results compared to control populations. Similarly, the risk was not increased in pregnancies with AFI below 97.5 percentile for gestational age (n¼54), as well as in cases diagnosed above 34 weeks (n¼75). However, pregnancies with isolated moderate and severe polyhydramnios, AFI above 97.5 percentile or cases diagnosed before 34 weeks were associated with significantly increased risk for clinically significant CMA findings. Of 64 cases of non-isolated polyhydramnios (most frequently associated with cardiovascular and brain anomalies), 5 (7.8%) % abnormal CMA findings were noted, a significantly higher rate compared to both control populations. In addition, non-isolated cohort yielded a significantly higher ratio of karyotype-detectable to submicroscopic aberrations (4/5, or 80.0%), compared to isolated cases (2/17, or 11.8%, p¼0.0026). CONCLUSION: An extensive anatomical sonographic survey must be performed in pregnancies with polyhydramnios, with consideration of fetal echocardiography. CMA testing should be recommended in pregnancies with polyhydramnios above 97.5 percentile for gestational age, cases diagnosed before 34 weeks, or those associated with additional sonographic findings, whereas mild or late polyhydramnios does not seem to increase the rate of chromosomal aberrations compared to pregnancies with normal ultrasound. OBJECTIVE: To conduct a pilot validation study for cell-based NIPT to assess the feasibility for performing a more rigorous CLIA validation. STUDY DESIGN: Thirty mL venous blood samples (EDTA) were studied from 42 singleton pregnancies (GA 8w-20w) including both low & high risk for chromosomal or other genetic abnormalities, of which 19 also underwent amnio or CVS. Fetal cells were recovered using RBC lysis and fetal cell magnetic bead enrichment with one internally developed and three commercial antibodies. Cells were identified as putatively fetal based on morphology and staining pattern, and picked individually for subsequent whole genome amplification and whole genome next generation sequencing (NGS)
